Karyopharm Therapeutics | KPTI - Current Liabilities


Karyopharm Therapeutics reported $117.3M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Abbott USD 16.15B 1.66B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck USD 28.8B 1.07B Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Takeda JPY 2.6T 161B Sep/2026
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Xencor USD 76.27M 5.6M Sep/2026